HAII participated in CES 2025, which opened on January 8, and received positive feedback from visitors for showcasing innovative AI-based digital healthcare services, including Mindcheck, the world’s first tool to diagnose depression and anxiety without a questionnaire.

CES, the world’s largest IT and consumer electronics exhibition, was held in Las Vegas, USA. With support from the National IT Industry Promotion Agency of Korea, HAII secured a dedicated booth in the digital healthcare section, marking 2025 as the year of global expansion. The company showcased four AI-based digital healthcare services, leveraging its technological expertise.

Among these, alzguard is a service that screens for dementia using digital biomarkers such as eye tracking, voice analysis, and cognitive response tests. Currently, confirmatory clinical services are being conducted at three major university hospitals in South Korea, with plans to expand globally in 2026 through collaborations with leading U.S. universities.

Mindcheck, an emotional disorder diagnostic service, uses one million data points accumulated over three years to diagnose stress, depression, and anxiety in just 40 seconds using HRV (heart rate variability) data, eliminating the need for cumbersome and subjective questionnaires. This groundbreaking service, unparalleled globally, received enthusiastic responses from attendees.

Additionally, HAII introduced repeech, which measures the severity of stroke-based language disorders using voice analysis, and a smartphone-based service for diagnosing sarcopenia, a growing concern among the elderly.

Jin-woo Kim, CEO of HAII, stated, “Since its incorporation in 2023, HAII has achieved significant milestones, including collaborations with two major U.S. medical schools for digital healthcare clinical trials. CES 2025 is an opportunity to share these achievements globally and gather valuable feedback on our AI-based emotional disorder and dementia diagnostic services as we prepare for global expansion.”

HAII is one of South Korea’s leading digital healthcare companies. In 2024, it completed confirmatory clinical trials for Anzeilax, a treatment for generalized anxiety disorder, and is awaiting approval from the Ministry of Food and Drug Safety. The company is also conducting confirmatory clinical trials for dementia diagnosis and post-stroke aphasia treatments.